Soleno Therapeutics (SLNO) Long-Term Investments (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Long-Term Investments data on file, last reported at $273.4 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $273.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $273.4 million (changed N/A YoY), and the FY2025 annual result was $200.6 million, up 637.26% from the prior year.
• Long-Term Investments climbed to $273.4 million in Q1 2026 per SLNO's latest filing, from $200.6 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $273.4 million in Q1 2026 and troughed at $7.0 million in Q2 2025.
• A 3-year average of $78.8 million and a median of $28.2 million in 2024 frame the typical range for Long-Term Investments.
• On a YoY basis, Long-Term Investments climbed as much as 637.26% in 2025 and fell as far as 75.43% in 2025.
• A 3-year view of Long-Term Investments shows it stood at $27.2 million in 2024, then soared by 637.26% to $200.6 million in 2025, then surged by 36.27% to $273.4 million in 2026.
• Business Quant data shows SLNO's Long-Term Investments at $273.4 million in Q1 2026, $200.6 million in Q4 2025, and $57.1 million in Q3 2025.